- Trials with a EudraCT protocol (41)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
41 result(s) found for: Heavy Chain.
Displaying page 1 of 3.
EudraCT Number: 2018-000029-29 | Sponsor Protocol Number: 95105003 | Start Date*: 2018-12-11 |
Sponsor Name:VU University Medical Center | ||
Full Title: Extra energy for hearts with a genetic defect: ENERGY trial | ||
Medical condition: Hypertrophic cardiomyopathy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004498-29 | Sponsor Protocol Number: 20190360 | Start Date*: 2022-01-13 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor... | |||||||||||||
Medical condition: Newly Diagnosed Philadelphia (Ph)-negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Trial now transitioned) SE (Trial now transitioned) AT (Ongoing) FI (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) IT (Ongoing) BE (Trial now transitioned) HU (Ongoing) BG (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002460-29 | Sponsor Protocol Number: EASIC30505 | Start Date*: 2005-09-12 |
Sponsor Name:Rheumazentrum Ruhrgebiet. | ||
Full Title: An Open Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC... | ||
Medical condition: Ankylosing spondylitis (AS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) FI (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000579-19 | Sponsor Protocol Number: MAGNET | Start Date*: 2021-06-25 |
Sponsor Name:Stichting TRICALS Foundation | ||
Full Title: A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) | ||
Medical condition: Amyotrophic Lateral Sclerosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003826-10 | Sponsor Protocol Number: EAGLE | Start Date*: 2014-01-24 |
Sponsor Name:IRCCS- Mario Negri Institute | ||
Full Title: EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA | ||
Medical condition: Membranoproliferative glomerulonephritis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017825-21 | Sponsor Protocol Number: EC09/081 | Start Date*: 2012-11-19 | |||||||||||
Sponsor Name:INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD | |||||||||||||
Full Title: Prospective, randomised, double-blind study to evaluate the efficacy of treatment with melatonin in adult patients with severe sepsis or septic shock. | |||||||||||||
Medical condition: Severe sepsis or septic shock. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000181-39 | Sponsor Protocol Number: C0168X84, EU-0108 | Start Date*: 2005-08-31 |
Sponsor Name:Med. Universitaetsklinik Graz, ao Univ. Professor Dr. med. Thomas C. Wascher | ||
Full Title: A Prospective Trial of Anti-TNF-a Chimeric Monoclonal Antibody (infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity | ||
Medical condition: Insulin Resistant Human Obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016703-35 | Sponsor Protocol Number: NAPMSv3.2 | Start Date*: 2010-01-08 | ||||||||||||||||
Sponsor Name:Dansk Multipel Sclerose Center | ||||||||||||||||||
Full Title: Natalizumabbehandling af progressiv multipel sklerose | ||||||||||||||||||
Medical condition: Secondary progressive multiple sclerosis and primary progressive multiple sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-000838-39 | Sponsor Protocol Number: MHE104317 | Start Date*: 2007-10-11 | |||||||||||
Sponsor Name:GlaxoSmithKline Resaearch and Development Ltd | |||||||||||||
Full Title: A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome | |||||||||||||
Medical condition: Hypereosinophilic Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NO (Completed) BE (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) PL (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000990-29 | Sponsor Protocol Number: IC2011-02 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:INSTITUT CURIE | |||||||||||||
Full Title: Multinational européan trial for children with the opsoclonus myoclonus syndrome/dancing eye syndrome. | |||||||||||||
Medical condition: Opsoclonus myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in children with and without neuroblastoma (NBpos and NBneg) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) SE (Ongoing) IT (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) ES (Ongoing) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001644-21 | Sponsor Protocol Number: MEA115661 | Start Date*: 2013-06-24 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials. | ||
Medical condition: Subjects with Severe Asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) NL (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-011606-41 | Sponsor Protocol Number: CP-MGA031-03 | Start Date*: 2009-09-15 | |||||||||||
Sponsor Name:MacroGenics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in C... | |||||||||||||
Medical condition: Recent-onset type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) NL (Prematurely Ended) ES (Temporarily Halted) FI (Completed) GB (Completed) DE (Completed) BE (Completed) PL (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022865-81 | Sponsor Protocol Number: ALX-0061-1.1/10 | Start Date*: 2011-03-02 | |||||||||||
Sponsor Name:Ablynx NV | |||||||||||||
Full Title: A phase I/II, multi-center, randomized, double-blind, placebo controlled study, with a single ascending dose part followed by a multiple ascending dose part, evaluating the safety, pharmacokinetics... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008432-82 | Sponsor Protocol Number: CP-MGA031-02 | Start Date*: 2009-07-01 | |||||||||||
Sponsor Name:MacroGenics, Inc. | |||||||||||||
Full Title: A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Chi... | |||||||||||||
Medical condition: Recent-onset type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) ES (Temporarily Halted) SE (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003349-13 | Sponsor Protocol Number: NOG112264 | Start Date*: 2012-12-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) IT (Completed) DE (Completed) GB (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002457-69 | Sponsor Protocol Number: CP-MGA031-01 | Start Date*: 2008-12-04 | |||||||||||
Sponsor Name:MacroGenics, Inc. | |||||||||||||
Full Title: A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-C... | |||||||||||||
Medical condition: Recent-onset type I diabetes mellitus (T1DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) CZ (Completed) SE (Completed) GB (Completed) EE (Completed) NL (Completed) LV (Completed) ES (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002549-39 | Sponsor Protocol Number: Ponatinib-1501 | Start Date*: 2020-12-07 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho... | |||||||||||||
Medical condition: acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) CZ (Completed) NL (Ongoing) IT (Ongoing) PL (Completed) PT (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003479-20 | Sponsor Protocol Number: 2011/433 | Start Date*: 2013-04-15 | |||||||||||
Sponsor Name:Handkirurgiska kliniken, Universitetssjukhuset Örebro | |||||||||||||
Full Title: Lateral humerus epicondylitis- a clinical, muscle morpological, muscle metabolical and functional evaluation of a new model for treatment. | |||||||||||||
Medical condition: Chronic lateral humerus epiconcylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001182-41 | Sponsor Protocol Number: C0168X97 | Start Date*: 2007-03-27 | |||||||||||
Sponsor Name:Ass.Prof. Petros Sfikakis | |||||||||||||
Full Title: Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-over, 32 Weeks Study | |||||||||||||
Medical condition: Diabetic Macular Oedema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001577-13 | Sponsor Protocol Number: CC-HCM-01 | Start Date*: 2014-07-15 | |||||||||||
Sponsor Name:Manchester University NHS Foundation Trust | |||||||||||||
Full Title: Copper Chelation in Hypertrophic Cardiomyopathy: Open-label pilot study of Trientine in patients with hypertrophic cardiomyopathy | |||||||||||||
Medical condition: Hypertrophic Cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.